NCT03516591View on ClinicalTrials.gov

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 22, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG

AMV564 14-Day CIV

A 14-Day Continuous Intravenous Infusion regimen

Trial Locations (5)

33612

Moffitt Cancer Center, Tampa

42310

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University, Siteman Cancer Center, St Louis

77030

MD Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

Sponsors
All Listed Sponsors
lead

Amphivena Therapeutics, Inc.

INDUSTRY

NCT03516591 - A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter